Slide 1: Forward Looking Statements
2 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the
Slide 2: Sales Growth and Core Sales Growth
bi DANAHER CORPORATION Sales Growth and Core Sales Growth % Estimated Change ‘Three-Month Porlod Total sales growth (GAAP) ++Mid-single digit Impact of: Acquisitionsidivestitures +Up slightly Currency exchange rates -Low-single digit Core sales growth (non-GAAP) tLow-single digit (Sin millions) [Nin
Slide 3: What You'll Hear Today
4 What You’ll Hear Today Anticipate Q4 2025 results will be slightly ahead of our expectations Differentiated positions in attractive areas of Biotechnology, Life Sciences and Diagnostics Well-positioned to generate sustainable long-term shareholder value through innovation, execution and capital de
Slide 4: Current Update
5 Current Update Solid execution drove a good finish to 2025 Anticipate Q4 2025 will be slightly ahead of our expectations Expect Q4 core revenue growth to be toward the high end of our low-single digit percentage guidance • Bioprocessing consumables +HSD and equipment +MSD • Good momentum across Di
Slide 5: Danaher Today
6 Danaher Today 1. Revenue metrics reflect estimated 2025 (“2025E”) results 2. Reflects 2024 Actual Results 2025E Total Revenue1 ~$24.5B DiagnosticsLife Sciences Biotechnology >$6B28.6%59.5% Operating Cash Flow2 Adj. Operating Profit Margin2 Gross Profit Margin2 Differentiated positioning with a
Slide 6: Differentiated business models and end-market positioning
7 Differentiated business models and end-market positioning Leading positions in attractive, fast-growing end markets • Long-term secular growth drivers • Regulatory requirements High-Quality Businesses in Attractive End Markets Pie charts are a % of 2025E total revenue Strategic End-Market Exposure
Slide 7: Leading Bioprocessing Franchise
9 Cell expansion & production Clarification Capture Viral inactivation Intermediate Polishing Viral filtration Formulation & sterile filtration Bulk fill Drug product fill Leading Bioprocessing Franchise Cell Culture & SUT Chromatography Filtration Drug Product Well-positioned for HSD core revenue g
Slide 8: Well-Positioned in Life Sciences
10 Well-Positioned in Life Sciences Pie chart percentages are % of 2025E revenues Expect HSD long-term core revenue growth with opportunity for margin expansion Strategic End-Market Exposure • Broad-based end-market exposure • Differentiated positions in analytical instrumentation & life sciences co
Slide 9: Innovation Helping Solve Some of Healthcare's Biggest Challenges
12 Innovation Helping Solve Some of Healthcare’s Biggest Challenges Accelerating Drug Discovery ~25% increase in new product revenue generated over the last year Increasing Biologic Manufacturing Yields Improving Patient Diagnoses Xcellerex X-platform Bioreactors Scalable platform designed to increa
Slide 10: Long-term value creation through strategic M&A
14 Long-term value creation through strategic M&A Meaningful capacity available to pursue value creation opportunities *2020 reflects reported results prior to the presentation of the Environmental & Applied Solutions businesses as discontinued operations; Today reflects Adjusted EBITDA from continu
Slide 11: Putting It All Together
16 Expect gradual improvement towards HSD long-term core revenue growth Expect core revenue growth to accelerate with end-market recovery Anticipated long-term annual performance Putting It All Together HSDCore revenue growth + 35-40%Operating profit fall-through + >100% FCF / NIStrong free cash flo
Slide 12: Adjusted EBITDA and Net Debt Reconciliation
bi DANAHER CORPORATION Nine-Month Period _Three-Month Period Ended September 26, Ended December 31, Year Ended 2028 2028 December 31, 2020" Net Earnings from Continuing Operations (GAAP) $ 2417 § 7,086 $ 3.646 Interest, Net 193 47 204 Other Nonoperating (Income) Expense 135, 63 (468) Income Taxes 44
Slide 13: Statement Regarding Non-GAAP Measures
‘Statement Regarding Non-GAAP Measures Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes